Printed Edition
A printed edition of this Special Issue is available at MDPI Books....
Identification of Two Novel Anti-Fibrotic Benzopyran Compounds Produced by Engineered Strains Derived from Streptomyces xiamenensis M1-94P that Originated from Deep-Sea Sediments
1
State Key Laboratory of Microbial Metabolism and School of Life Science & Biotechnology, State Key Laboratory of Ocean Engineering, Shanghai Jiao Tong University, Shanghai 200240, China
2
State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200240, China
3
Ministry of Education Key Laboratory of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai 200240, China
4
Key Laboratory of Marine Biogenetic Resources, the Third Institute of Oceanography SOA, Xiamen 361005, Fujian, China
5
Instrumental Analysis Center, Shanghai Jiao Tong University, Shanghai 200240, China
*
Author to whom correspondence should be addressed.
Mar. Drugs 2013, 11(10), 4035-4049; https://doi.org/10.3390/md11104035
Received: 17 August 2013 / Revised: 16 September 2013 / Accepted: 26 September 2013 / Published: 22 October 2013
(This article belongs to the Special Issue Advances and New Perspectives in Marine Biotechnology)
The benzopyran compound obtained by cultivating a mangrove-derived strain, Streptomyces xiamenensis strain 318, shows multiple biological effects, including anti-fibrotic and anti-hypertrophic scar properties. To increase the diversity in the structures of the available benzopyrans, by means of biosynthesis, the strain was screened for spontaneous rifampicin resistance (Rif), and a mutated rpsL gene to confer streptomycin resistance (Str), was introduced into the S. xiamenensis strain M1-94P that originated from deep-sea sediments. Two new benzopyran derivatives, named xiamenmycin C (1) and D (2), were isolated from the crude extracts of a selected Str-Rif double mutant (M6) of M1-94P. The structures of 1 and 2 were identified by analyzing extensive spectroscopic data. Compounds 1 and 2 both inhibit the proliferation of human lung fibroblasts (WI26), and 1 exhibits better anti-fibrotic activity than xiamenmycin. Our study presents the novel bioactive compounds isolated from S. xiamenensis mutant strain M6 constructed by ribosome engineering, which could be a useful approach in the discovery of new anti-fibrotic compounds.
View Full-Text
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License
MDPI and ACS Style
You, Z.-Y.; Wang, Y.-H.; Zhang, Z.-G.; Xu, M.-J.; Xie, S.-J.; Han, T.-S.; Feng, L.; Li, X.-G.; Xu, J. Identification of Two Novel Anti-Fibrotic Benzopyran Compounds Produced by Engineered Strains Derived from Streptomyces xiamenensis M1-94P that Originated from Deep-Sea Sediments. Mar. Drugs 2013, 11, 4035-4049.
Show more citation formats- Supplementary File 1:
Supplementary Materials (PDF, 1338 KB)
- Supplementary File 2:
3D structure (MOL, 2 KB)
Display in MOL Viewer
3D structure generated by CORINA by Molecular Networks. - Supplementary File 3:
MOL-Document (MOL, 2 KB)
Display in MOL Viewer
- Supplementary File 4:
3D structure (MOL, 3 KB)
Display in MOL Viewer
3D structure generated by CORINA by Molecular Networks. - Supplementary File 5:
MOL-Document (MOL, 3 KB)
Display in MOL Viewer
